华大智造前三季度净利亏损1.2亿元，同比减亏

Core Viewpoint - BGI Genomics (688114) reported a slight decline in revenue for the first three quarters of 2025, but managed to reduce its net loss compared to the previous year [2]. Financial Performance - The company's revenue for the first three quarters was 1.869 billion yuan, representing a year-on-year decrease of 0.01% [2]. - The net profit attributable to shareholders was -120 million yuan, indicating a reduction in losses compared to the same period last year [2]. Key Factors Influencing Performance - The reduction in net loss was primarily due to the company's ongoing efforts to reduce costs and improve efficiency, resulting in a significant decrease in expenses compared to the same period last year [2]. - Fluctuations in the exchange rates of the US dollar and euro led to an increase in foreign exchange gains from foreign currency monetary items compared to the previous year [2]. - The reversal of tax provisions related to uncertainties from previous years contributed to a decrease in income tax expenses year-on-year [2].